MGX (Metagenomi Therapeutics) Total Assets: $196.95 Mil (As of Mar. 2026)


MGX Metagenomi Therapeutics Inc MGX
10 GF Score
Price $1.26
! 4 Warning Signs
View Full Analysis

What is Metagenomi Therapeutics Total Assets?

Metagenomi Therapeutics MGX +4.13% 10 Total Assets is $196.95 Mil as of Mar. 2026. GuruFocus rates MGX with a GF Score™ of 10/100. The stock has 4 warning signs investors should review.

Metagenomi Therapeutics's Total Assets for the quarter that ended in Mar. 2026 was $196.95 Mil.

During the past 12 months, Metagenomi Therapeutics's average Total Assets Growth Rate was -21.00% per year. During the past 3 years, the average Total Assets Growth Rate was 4.80% per year.

During the past 5 years, Metagenomi Therapeutics's highest 3-Year average Total Assets Growth Rate was 31.10%. The lowest was 4.80%. And the median was 17.95%.

Total Assets is connected with ROA %. Metagenomi Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 was -44.13%. Total Assets is also linked to Revenue through Asset Turnover. Metagenomi Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 was 0.01.

Metagenomi Therapeutics  (NAS:MGX) Total Assets Explanation

Total Assets is connected with ROA %.

Metagenomi Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-92.236/( (221.103+196.953)/ 2 )
=-92.236/209.028
=-44.13 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Metagenomi Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=1.248/( (221.103+196.953)/ 2 )
=1.248/209.028
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Metagenomi Therapeutics Total Assets Related Terms

Metagenomi Therapeutics Total Assets Historical Data

* Premium members only.

The historical data trend for Metagenomi Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Metagenomi Therapeutics Total Assets Chart

Metagenomi Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
141.99 414.49 364.84 324.60 221.10

Metagenomi Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 297.87 272.28 247.94 221.10 196.95
MGX
10GF Score
Metagenomi Therapeutics Inc MGX
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Metagenomi Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Metagenomi Therapeutics's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=158.596+62.507
=221.10

Metagenomi Therapeutics's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=137.785+59.168
=196.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $196.95 Mil mean?
Metagenomi Therapeutics (MGX) has a Total Assets of $196.95 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Metagenomi Therapeutics and its competitors.
Is Metagenomi Therapeutics' Total Assets too high?
Metagenomi Therapeutics' current Total Assets is $196.95 Mil. Overall, Metagenomi Therapeutics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Metagenomi Therapeutics' Total Assets compare to KALA and HYPD?
Metagenomi Therapeutics' Total Assets of $196.95 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Metagenomi Therapeutics and its competitors. Metagenomi Therapeutics's current Total Assets is $196.95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metagenomi Therapeutics stock overvalued right now?
Metagenomi Therapeutics (MGX) has a current Total Assets of $196.95 Mil. The current Total Assets is $196.95 Mil. Metagenomi Therapeutics' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Metagenomi Therapeutics (MGX), the current Total Assets is $196.95 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Metagenomi Therapeutics Business Description

Address 5959 Horton Street, 7th Floor, Emeryville, CA, USA, 94608
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
10GF Score

Get the complete analysis for MGX

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.26
Price